On Aug. 15, the Food and Drug Administration (FDA) issued new guidance aimed at assisting institutional review boards (IRBs), clinical investigators and sponsors in complying with the FDA’s informed consent requirements for...more
On Friday, April 7, both the Northern District of Texas and the Eastern District of Washington issued decisions impacting the Food and Drug Administration’s (FDA) approval of the abortion drug mifepristone. The Texas decision...more
4/17/2023
/ Abortion ,
Dobbs v. Jackson Women’s Health Organization ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Injunctive Relief ,
Judicial Intervention ,
Patient Access ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Authority ,
Regulatory Standards ,
Reproductive Healthcare Issues ,
Stays